(Q36099478)

12 August 2017

1 reference

title

Efalizumab: continuous therapy for chronic psoriasis (English)

1 reference

12 August 2017

Jennifer Clay Cather

1

1 reference

12 August 2017

Alan Menter

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

393-403

1 reference

Epidemiology of psoriasis

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Quality of life in patients with psoriasis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

An approach to the treatment of moderate to severe psoriasis with rotational therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Novel biological immunotherapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

The role of T cells in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

The immunologic basis for the treatment of psoriasis with new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.393

21 January 2018

Identifiers

DOI

10.1517/14712598.5.3.393

1 reference

12 August 2017

1 reference